Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.21%)
Updated Sep 20, 2024 03:59 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ITRM 1.06 -0.04(-3.21%)
Will ITRM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITRM
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Other News for ITRM
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug
Iterum provides update on FDA advisory committee discussion on oral sulopenem
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript